Early Access — free while we kick the tires
EdgarHawk

Ghiath M. Sukhtian

Director

Director 10% Owner

Latest: Director buying · May 2026

1 filing analyzed · 1 company · Latest 2026-06-01

Never miss a filing from Ghiath M. Sukhtian

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
Outlook Therapeutics, Inc. OTLK 1 0 Net buying

Activity

June 2026
2026-06-01 Outlook Therapeutics, Inc. OTLK Cluster Joint filing
high
Buy
8,539,709 shares
$5,000,000
Significance 6/10

Director Sukhtian acquired 8,539,709 shares of OTLK at $0.59 ($5.0M) via private placement; 4 other insiders bought in prior 14 days.

Ghiath M. Sukhtian, Director, acquired 8,539,709 shares at $0.59 on 2026-05-28 for a total of $4,999,999.62, increasing his non-derivative holding from 13,552,359 to 22,092,068 shares (+63.0%). However, this transaction is a private placement—not a discretionary open-market purchase—and therefore does not signal insider conviction driven by market conditions. The larger context includes a cluster pattern: 4 other insiders also bought within the past 14 days, and the company is operating unprofitably with net income of $-4,453,081.00 against revenue of $1,505,322.00 in the latest quarter. Sukhtian's position also includes substantial derivative holdings (15,488,570 total warrant shares across six ownership vehicles), meaning his overall economic interest extends well beyond the non-derivative shares recorded in this Form 4. The current stock price of $0.84 represents a -75.2% drawdown from the 52-week high of $3.39, though the 30-day and 90-day price movements (+220.4% and +99.2%, respectively) suggest recent volatility. The multi-insider participation and private placement structure should be tracked to understand capitalization dynamics and warrant vesting schedules.

Related insiders